Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Discontinuation and Switching Study in Glucocorticoid-Induced Osteoporosis
2020-004903-15Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of denosumab in glucocorticoid-induced osteoporosis (GIOP) (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Primary outcome: change in CTX between randomization and 6 months. Started Oct 2021; status: completed.
02
Drugs
denosumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on 2020-004903-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004903-15.